Our bench strength is in our extensive experience and team approach. We strive to facilitate each of our client’s needs through strategy, research, and collaboration.
Dr. Hochadel has 30+ years of experience in the planning, managing, and conducting of clinical research trials. His Phase I clinical experience includes multiple dose studies in healthy elderly subjects, tyramine challenge pressor tests, and extensive evaluations of novel delivery systems (e.g. transdermal, nasal, and pulmonary delivery systems) including pharmacokinetic and wearability assessments.
His expertise in Phase II-IV development is highlighted by his work in dementia, including 48-week chronic dosing studies in Alzheimer’s disease subjects and nursing home-based studies targeting behavioral signs and symptoms. He also has significant experience with schizophrenia, movement disorders (including Parkinson’s disease, ataxia, and tardive dyskinesia), depression, bipolar disorder, attention deficit/hyperactivity disorder, obsessive-compulsive disorder, and sleep disorder trials. Dr. Hochadel was also responsible for an anti-osteoporosis compound IND and a development program.
Dr. Hochadel was one of the original founders of Cognitive Research Corporation in 2006 initially serving as Chief Operating Officer. His reputation for integrity and expertise in all areas of CNS brought many early clients to CRC, many of who are still working with the company. Dr. Hochadel’s focus on team building and transparent collaborations with sponsors created the foundation of the culture and performance at CRC. He continues to lead the company as President today.
Prior to CRC, Dr. Hochadel was Senior Director of Psychiatry and Neurology with SCIREX Corporation and Director of Clinical Operations (CNS Center) at Covance, Inc. At Covance, he actively managed senior project managers, cross-functional project teams, and all clinical aspects of central nervous system studies. He also served as Director of Clinical Research at Somerset Pharmaceuticals, Inc. for six years, during which he created preclinical-to-post-marketing development plans and regulatory submissions. During his time at Somerset, Dr. Hochadel conducted more than 30 Phase I clinical studies and was the driving force behind multiple IND applications. He also held the role of President of Advanced Research Corporation, where he was responsible for the overall management and financial health of a full-service contract research organization.
Dr. Hochadel earned his Pharm.D. from Mercer University Southern School of Pharmacy in Atlanta, Georgia. He also holds a B.S. degree in natural sciences from the University of South Florida. Dr. Hochadel is a registered pharmacist and participates in international medical missions.